erlotinib hydrochloride has been researched along with Cells, Neoplasm Circulating in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, A; Ito, S; Kaneda, N; Kodera, Y; Nakanishi, H; Sakao, Y; Yatabe, Y; Yoshimura, M | 1 |
| Adorno-Cruz, V; Chang, YF; Cristofanilli, M; Dashzeveg, NK; El-Shennawy, L; Jia, Y; Kawaguchi, M; Liu, H; Liu, X; Patel, D; Ramos, EK; Schuster, EJ; Taftaf, R; Zhang, Y | 1 |
| Abraham, E; Albright, C; Alistar, AT; Bitting, RL; Blackstock, W; Chen, K; D'Agostino, RB; Desnoyers, RJ; DeYoung, B; Foley, KL; Goodman, M; Grant, SC; Kytola, V; Levine, EA; Nykter, M; Pagni, M; Pasche, B; Petro, RM; Petty, WJ; Porosnicu, M; Powell, BL; Qasem, SA; Robinson, M; Staren, ED; Thomas, A; Topaloglu, U; Vatca, M; Yang, M; Zhang, W | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Anderson, J; Baker, K; Gadi, V; Garrison, M; Gralow, J; Jenkins, I; Korde, L; Kurland, B; Linden, H; Redman, M; Rodler, E; Smith, J; Specht, J; Symonds, L; Van Haelst, C; Wu, QV | 1 |
| Burton, L; Cowan, KJ; Hampton, GM; Hegde, PS; Lackner, MR; Li, C; Merchant, M; Parab, V; Patel, P; Penuel, E; Peterson, A; Yauch, RL | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Bekaii-Saab, T; Collisson, EA; Courtin, R; Dito, E; Joseph, NM; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Linetskaya, R; Mirzoeva, OM; Ong, A; Tahiri, S; Talasaz, A; Tempero, MA; Van Ziffle, J; Venook, AP; Ziyeh, S | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Boucher, D; Costa, DB; Dahlberg, SE; Feeney, N; Jackman, DM; Jänne, PA; Johnson, BE; O'Connell, A; Oxnard, GR; Paweletz, CP; Redig, AJ; Taibi, M; Yanagita, M | 1 |
| Amler, LC; Atwal, S; Fine, BM; Hampton, GM; Hicks, RJ; Hughes, BG; Lackner, MR; Liu, W; Pirzkall, A; Punnoose, EA; Raja, R | 1 |
8 trial(s) available for erlotinib hydrochloride and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Tubulin Modulators | 2019 |
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers; DNA, Neoplasm; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Retreatment | 2016 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Prospective Studies; Protein Kinase Inhibitors | 2016 |
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Quinazolines | 2012 |
3 other study(ies) available for erlotinib hydrochloride and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human
Topics: Animals; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Heterografts; Humans; Immunohistochemistry; Mice; Mutation; Neoplastic Cells, Circulating; Receptor, ErbB-2; Stomach Neoplasms | 2019 |
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cell Aggregation; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, Reporter; Humans; Hyaluronan Receptors; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Neoplasm Proteins; Neoplastic Cells, Circulating; Neoplastic Stem Cells; RNA; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Clone Cells; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genes, erbB-1; Genes, Neoplasm; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Protein Kinase Inhibitors; Retrospective Studies; Sequence Analysis, DNA; Smoking | 2017 |